| http://purl.uniprot.org/citations/26285213 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/26285213 | http://www.w3.org/2000/01/rdf-schema#comment | "One of the most common adverse event of interferon beta (IFNβ) therapy for multiple sclerosis is flu-like syndrome (FLS), which has been reportedly related to increased levels of cytokines such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Average cytokine levels can be affected by single nucleotide polymorphism in the gene promoter regions. To investigate whether IL-6 -174 G>C and TNF-α -376 G>A polymorphisms could be correlated to the incidence of FLS, and whether an anti-inflammatory/antipyretic therapy may influence FLS development, a prospective observational study was performed in 190 treatment naïve, multiple sclerosis patients who started IM IFNβ-1a 30mcg once weekly. The identification of IL-6 -174 G>C and TNF-α -376 G>A polymorphisms was achieved by performing an amplification-refractory mutation system. Serum IL-6 levels were measured using enzyme-linked immunosorbent assay in blood samples taken before therapy and then after the first and last IFNβ-1a injection of the follow-up. FLS-related symptoms were recorded by patients once per week during the first 12 weeks of therapy into a self-reported diary. We found that patients carrying at least one copy of the C allele at position -174 in the promoter of IL-6 gene produced lower levels of IL-6 and were less prone to develop FLS, which was also less severe. On the contrary, the polymorphism of TNF-α had no effect on FLS. Patients taking the first dose of anti-inflammatory/antipyretic therapy in the peri-injection period (within 1 hour) experienced a reduced FLS severity. In conclusion, the study of IL-6 -174 G>C polymorphism would allow the identification of patients lacking the C nucleotide on both alleles who are at risk of a more severe FLS, and may be addressed to a timely and stronger anti-inflammatory/antipyretic therapy for a more effective FLS prevention."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.org/dc/terms/identifier | "doi:10.1371/journal.pone.0135441"xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Centonze D."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Florio C."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Capra R."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Imberti L."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Sottini A."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Amato M.P."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Cordioli C."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Serana F."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Bertoli D."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Maimone D."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/author | "Puma E."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/date | "2015"xsd:gYear |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/name | "PLoS One"xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/pages | "e0135441"xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/title | "Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene."xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://purl.uniprot.org/core/volume | "10"xsd:string |
| http://purl.uniprot.org/citations/26285213 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/26285213 |
| http://purl.uniprot.org/citations/26285213 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/26285213 |
| http://purl.uniprot.org/uniprot/#_A0A1C9J7U0-mappedCitation-26285213 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/26285213 |
| http://purl.uniprot.org/uniprot/#_B4DVM1-mappedCitation-26285213 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/26285213 |
| http://purl.uniprot.org/uniprot/#_B4DNV3-mappedCitation-26285213 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/26285213 |
| http://purl.uniprot.org/uniprot/#_B4DNQ5-mappedCitation-26285213 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/26285213 |